SBI-200

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameSBI-200
Drug Alias Namesynthetic cannabidiol derivative (emerald health therapeutics)SBI-200
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid receptor modulators
TargetsCannabinoid receptor
Therapy Area/IndicationsUveitisMacular DegenerationDiabetic Retinopathy +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSkye Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesSkye Bioscience Inc
Inactive CompaniesN/A
Active IndicationsUveitisMacular DegenerationDiabetic Retinopathy +[5] 
Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A